Market Place
Sourcing Support
Kyowa Kirin, Kura Oncology Start Japanese Phase 2 Trial
24 Apr 2026 //
GLOBENEWSWIRE
Trevi raises $150M; Spain and Boston set up biotech fund
17 Apr 2026 //
ENDPOINTS NEWS
Kura Oncology To Present Darlifarnib Plus Cabozantinib Data
09 Apr 2026 //
GLOBENEWSWIRE
Kura Oncology Issues Inducement Grants Under Nasdaq Rules
06 Mar 2026 //
GLOBENEWSWIRE
Kura Oncology Reveals 2025 Financial Performance
05 Mar 2026 //
GLOBENEWSWIRE
Kura Oncology to Participate in Three Investor Conferences
25 Feb 2026 //
GLOBENEWSWIRE
Kura Oncology Highlights KOMZIFTI Revenue, 2026 Milestones
11 Jan 2026 //
GLOBENEWSWIRE
Kura Oncology Reports Inducement Grants Under Nasdaq Rule
05 Jan 2026 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Present KOMZIFTI Data In AML
08 Dec 2025 //
GLOBENEWSWIRE
Kura Oncology Hosts Investor Event On ASH 2025 Data
03 Dec 2025 //
GLOBENEWSWIRE
Kura Oncology Nets $135M from First U.S. KOMZIFTI Sale
02 Dec 2025 //
GLOBENEWSWIRE
KOMZIFTI™ (Ziftomenib) Included In (NCCN) Guidelines For AML
25 Nov 2025 //
GLOBENEWSWIRE
Kura Oncology & Kirin Announce FDA Approval of Komzifti
13 Nov 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin To Present Ziftomenib Ven/Aza Data
03 Nov 2025 //
GLOBENEWSWIRE
Kura Oncology Gets Second $30M Payment For AML Menin Inhibitor
03 Nov 2025 //
GLOBENEWSWIRE
Kura Oncology Gets $30M Milestone Payment For Ziftomenib AML
24 Oct 2025 //
GLOBENEWSWIRE
Kura Oncology Unveils Early (FTI) Program Data At 2025 ESMO
18 Oct 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Initiate Trial For AML Patients
01 Oct 2025 //
GLOBENEWSWIRE
Kura, Kyowa Kirin Dose First Patient in AML Ph 3 Trial
29 Sep 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Publish Ziftomenib Data
25 Sep 2025 //
GLOBENEWSWIRE
Kura Oncology Showcases Farnesyl Transferase Inhibitors
16 Sep 2025 //
GLOBENEWSWIRE
Kura Oncology Reports Second Quarter 2025 Financial Results
07 Aug 2025 //
GLOBENEWSWIRE
Kura Oncology issues Inducement Grants per Nasdaq Rule 5635(c)(4)
04 Aug 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Report Positive Ziftomenib Data
02 Jun 2025 //
GLOBENEWSWIRE
Kura Oncology and Kyowa Kirin`s Ziftomenib NDA Accepted by FDA
01 Jun 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Present Ziftomenib Data at ASCO
22 May 2025 //
GLOBENEWSWIRE
Kura Oncology: First Patients Dosed in Ziftomenib Trial
28 Apr 2025 //
GLOBENEWSWIRE
Kura Oncology to Present Preclinical Data at 2025 AACR Meeting
26 Mar 2025 //
GLOBENEWSWIRE
Kura Oncology Reports 2024 Financial Results
26 Feb 2025 //
GLOBENEWSWIRE
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
22 Nov 2024 //
PR NEWSWIRE
